Drugs / hPV19
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03503604 | May 2018 → Jan 2019 | cancer | SuZhou Stainwei Biotech Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hPV19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03503604 ↗ |
| Action | Inhibit | “inhibits the binding of VEGF to it's receptors, VEGF-R1 and VEGF-R2.” NCT03503604 ↗ |
| Modality | Monoclonal antibody | “hPV19 is a monoclonal antibody (mAb) directed against vascular endothelial growth factor (VEGF).” NCT03503604 ↗ |
| Route | Intravenous | “hPV19 will give to patients by intravenous(i.v.) infusion” NCT03503604 ↗ |